KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company's Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for its investigational drug candidates across the majority of solid tumor types. The company's Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/20 | undisclosed |
Esperante | undisclosed | |
| 04/30/21 | $2,500,000 |
Seae Ventures | undisclosed | |
| 12/12/22 | $18,000,000 | Series C |
Bruker Corporation LabCorp Seae Ventures VentureSouth | undisclosed |
